Clinical trial
A Phase 3, Open-label, Non-controlled, Multi-dose, Extension Study to Evaluate the Long-term Safety and Tolerability of IGSC, 20% in Japanese Subjects With Primary Immunodeficiency Disease (PID)
NCT04842643 is registered in ClinicalTrials.gov with Takeda as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Open-label, Non-controlled, Multi-dose, Extension Study to Evaluate the Long-term Safety and Tolerability of IGSC, 20% in Japanese Subjects With Primary Immunodeficiency Disease (PID)
- Lead sponsor
- Takeda
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- April 27, 2021
- Completion date
- April 25, 2024
- Enrollment
- 12 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.
primary immunodeficiency disease